arino et al.' have performed a meta-analysis using data extracted M from published randomized trials comparing radiotherapy (RT) to RT plus chemotherapy (CT) in Stage IIIA and IIIB unresectable nonsmall cell lung cancer (NSCLC). They identified 14 trials published between 1980 and 1994. The odds rat
Adjuvant radiotherapy versus combined sequential chemotherapy followed by radiotherapy in the treatment of resected nonsmall cell lung carcinoma. A randomized trial of 267 patients
✍ Scribed by Bertrand Dautzenberg; Claude Chastang; Rodrigo Arriagada; Thierry Le Chevalier; Dominique Belpomme; Michel Hurdebourcq; Bernard Lebeau; Christiane Fabre; Patrick Charvolin; Robert A. Guérin
- Publisher
- John Wiley and Sons
- Year
- 1995
- Tongue
- English
- Weight
- 628 KB
- Volume
- 76
- Category
- Article
- ISSN
- 0008-543X
No coin nor oath required. For personal study only.
📜 SIMILAR VOLUMES
Background. For patients with Stage I11 nonsmall cell lung cancer (NSCLC), radiation is the standard treatment, but survival remains poor. The authors performed a meta-analysis study using clinical trials that evaluated combined radiotherapy plus chemotherapy versus radiotherapy alone in patients wi
## BACKGROUND. Surgery remains the treatment of choice for patients with esophageal squamous cell carcinoma (SCC), but survival rates have not improved over the past decades. The objective of this study was to evaluate the effect of multimodal therapy on resectability, on the overall and on diseas
## Background: Combination chemotherapy comprised of oral uft (a combination of tegafur and uracil) and cisplatin was shown to be an effective regimen for the treatment of advanced nonsmall cell lung carcinoma and to be associated with a low incidence rate of toxicity in a previous, single institut
## BACKGROUND. The aim of this trial was to compare the outcome achieved with neoadjuvant chemotherapy followed by radiotherapy to that achieved with radiotherapy alone for patients with locoregionally advanced undifferentiated or poorly differentiated nasopharyngeal carcinoma (NPC) meeting one of